Get the Stockscreener App
2.00
1.48%
-0.03
After Hours:
1.95
-0.05
-2.50%
Alx Oncology Holdings Inc stock is traded at $2.00, with a volume of 827.26K.
It is down -1.48% in the last 24 hours and up +19.76% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$2.03
Open:
$2.04
24h Volume:
827.26K
Relative Volume:
0.93
Market Cap:
$269.13M
Revenue:
-
Net Income/Loss:
$-101.70M
P/E Ratio:
-1.0548
EPS:
-1.8961
Net Cash Flow:
$-84.35M
1W Performance:
-3.85%
1M Performance:
+19.76%
6M Performance:
+22.70%
1Y Performance:
+357.25%
1-Day Range:
$1.95
$2.07
1-Week Range:
$1.93
$2.185
52-Week Range:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.00 | 273.16M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Mar-06-26 | Resumed | UBS | Buy |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
Is ALX Oncology Holdings (ALXO) outperforming other medical stocks this year? - MSN
Redmile Group, ALXO: Investment manager discloses 6.8% ownership - Stock Titan
HBM Healthcare (ALXO) discloses 8.59M shares, ~6.5% stake - Stock Titan
Earnings call transcript: ALX Oncology beats Q1 2026 earnings forecast - Investing.com
Q2 EPS Estimates for ALX Oncology Raised by HC Wainwright - MarketBeat
TradingKey - TradingKey
A Quick Look at Today's Ratings for ALX Oncology(ALXO.US), With a Forecast Between $4 to $6 - Moomoo
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q1 2026 Earnings Call Transcript - Insider Monkey
Alx Oncology Signals Promise, But Validation Looms - TipRanks
ALX Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS - MSN
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Moomoo
ALXO: ALX Oncology Reports Promising Data on CD47 Biomarker in H - GuruFocus
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
ALX ONCOLOGY ($ALXO) Releases Q1 2026 Earnings - Moomoo
ALX Oncology Holdings Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALXO) 2026-05-08 - Seeking Alpha
ALX Oncology Q1 Earnings Call Highlights - Barchart.com
Earnings call transcript: ALX Oncology Q1 2026 reveals clinical progress By Investing.com - Investing.com Canada
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
ALX Oncology Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ALX Oncology 1Q Loss/Shr 17c >ALXO - Moomoo
ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data - ChartMill
ALX Oncology Q1 2026 Earnings Call Transcript - MarketBeat
ALX Oncology Holdings 1Q 2026: Net income $(17.9M), EPS $(0.17) — 10-Q Summary - TradingView
[10-Q] ALX ONCOLOGY HOLDINGS INC Quarterly Earnings Report - Stock Titan
ALX Oncology reports Q1 net loss of $17.9M, cash $169.1M; advances evorpacept and ALX2004 programs - TradingView
ALXO: Durable clinical responses and reduced net loss highlight progress in HER2-positive cancer trials - TradingView
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ALX Oncology (NASDAQ: ALXO) cuts Q1 loss, raises $150M for cancer pipeline - Stock Titan
ALX Oncology reports all 5 high-CD47 breast cancer patients responded - Stock Titan
ALX Oncology reports breast cancer trial data with CD47 biomarker - Investing.com UK
MSN Money - MSN
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - Investing News Network
ALX Oncology reports breast cancer trial data with CD47 biomarker By Investing.com - Investing.com Australia
Insiders Buying ALX Oncology Holdings Might Wish They Invested More, Stock Gains 32% - Moomoo
Alx Oncology's evorpacept in combination with zanidatamab generates promising, durable response in patients with advanced her2-positive breast cancer and high cd47 expression - marketscreener.com
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - The Manila Times
In ALX breast cancer study, 5 of 5 high-CD47 patients responded - Stock Titan
ALX Oncology Holdings Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
ALXO SEC FilingsAlx Oncology Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ALX Oncology (ALXO.US) will release its earnings report before the market opens on May 8. - Moomoo
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Announces That CD47 Biomarker Data from - GlobeNewswire
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 - The Manila Times
BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN
ALX Oncology (ALXO) amendment shows Millennium affiliates report 1.99M shares - Stock Titan
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Mar 19 '26 |
Sale |
2.17 |
903 |
1,960 |
86,805 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 18 '26 |
Sale |
2.27 |
565 |
1,283 |
87,708 |
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):